275 related articles for article (PubMed ID: 29558251)
1. Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer.
Lau SKM; Gannavarapu BS; Carter K; Gao A; Ahn C; Meyer JJ; Sher DJ; Jatoi A; Infante R; Iyengar P
J Oncol Pract; 2018 Apr; 14(4):e211-e220. PubMed ID: 29558251
[TBL] [Abstract][Full Text] [Related]
2. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer.
Mytelka DS; Li L; Benoit K
J Cachexia Sarcopenia Muscle; 2018 Feb; 9(1):86-92. PubMed ID: 29205930
[TBL] [Abstract][Full Text] [Related]
3. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Cancer; 2008 May; 112(9):2011-20. PubMed ID: 18361399
[TBL] [Abstract][Full Text] [Related]
4. Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non-Small Cell Lung Cancer.
Alvarez CM; Aliru M; Gannavarapu BS; Song T; Gilmore LA; Olaechea S; Gomez DR; Ahn C; Infante RE; Iyengar P
Am J Clin Oncol; 2024 Feb; 47(2):49-55. PubMed ID: 38011024
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Survival Impact of Pretreatment Cancer-Associated Weight Loss: A Tool for Guiding Early Palliative Care.
Gannavarapu BS; Lau SKM; Carter K; Cannon NA; Gao A; Ahn C; Meyer JJ; Sher DJ; Jatoi A; Infante R; Iyengar P
J Oncol Pract; 2018 Apr; 14(4):e238-e250. PubMed ID: 29466074
[TBL] [Abstract][Full Text] [Related]
6. Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status.
Tannenbaum SL; Koru-Sengul T; Zhao W; Miao F; Byrne MM
Cancer J; 2014; 20(4):237-45. PubMed ID: 25098282
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
Takayama K; Atagi S; Imamura F; Tanaka H; Minato K; Harada T; Katakami N; Yokoyama T; Yoshimori K; Takiguchi Y; Hataji O; Takeda Y; Aoe K; Kim YH; Yokota S; Tabeta H; Tomii K; Ohashi Y; Eguchi K; Watanabe K
Support Care Cancer; 2016 Aug; 24(8):3473-80. PubMed ID: 27003901
[TBL] [Abstract][Full Text] [Related]
8. Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer.
Ahn DH; Mehta N; Yorio JT; Xie Y; Yan J; Gerber DE
Clin Lung Cancer; 2013 Nov; 14(6):644-50. PubMed ID: 23886797
[TBL] [Abstract][Full Text] [Related]
9. Distance from accessible specialist care and other determinants of advanced or unknown stage at diagnosis of people with non-small cell lung cancer: A data linkage study.
Tracey E; McCaughan B; Badgery-Parker T; Young J; Armstrong B
Lung Cancer; 2015 Oct; 90(1):15-21. PubMed ID: 26275475
[TBL] [Abstract][Full Text] [Related]
10. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Socioeconomic Status on Treatment and Mortality in Non-Small Cell Lung Cancer Patients.
Ebner PJ; Ding L; Kim AW; Atay SM; Yao MJ; Toubat O; McFadden PM; Balekian AA; David EA
Ann Thorac Surg; 2020 Jan; 109(1):225-232. PubMed ID: 31472134
[TBL] [Abstract][Full Text] [Related]
12. Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
Vinod SK; Chandra A; Berthelsen A; Descallar J
Lung Cancer; 2017 Oct; 112():16-24. PubMed ID: 29191589
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study.
Shukuya T; Takahashi K; Shintani Y; Miura K; Sekine I; Takayama K; Inoue A; Okamoto I; Kiura K; Kawaguchi T; Yamamoto N; Miyaoka E; Yoshino I; Date H
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1274-1285. PubMed ID: 36905129
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Payer Status on Survival of Patients with Stage I/II Non-small Cell Lung Cancer: NCDB 1998-2011.
Shi R; Diaz R; Shi Z; Duvall E; Mills G
Anticancer Res; 2016 Jan; 36(1):319-26. PubMed ID: 26722060
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
17. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis.
Lara MS; Brunson A; Wun T; Tomlinson B; Qi L; Cress R; Gandara DR; Kelly K
Lung Cancer; 2014 Aug; 85(2):264-9. PubMed ID: 24878033
[TBL] [Abstract][Full Text] [Related]
18. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
[TBL] [Abstract][Full Text] [Related]
19. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
Rice SR; Vyfhuis MAL; Scilla KA; Burrows WM; Bhooshan N; Suntharalingam M; Edelman MJ; Feliciano J; Badiyan SN; Simone CB; Bentzen SM; Feigenberg SJ; Mohindra P
Clin Lung Cancer; 2020 May; 21(3):e130-e141. PubMed ID: 31708388
[TBL] [Abstract][Full Text] [Related]
20. Patient education level as a predictor of survival in lung cancer clinical trials.
Herndon JE; Kornblith AB; Holland JC; Paskett ED
J Clin Oncol; 2008 Sep; 26(25):4116-23. PubMed ID: 18757325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
